These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9347379)

  • 1. Long-term treatment of psychotic (delusional) depression with fluvoxamine: an open pilot study.
    Zanardi R; Franchini L; Gasperini M; Smeraldi E; Perez J
    Int Clin Psychopharmacol; 1997 Jul; 12(4):195-7. PubMed ID: 9347379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study.
    Zanardi R; Franchini L; Serretti A; Perez J; Smeraldi E
    J Clin Psychiatry; 2000 Jan; 61(1):26-9. PubMed ID: 10695642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression.
    Franchini L; Gasperini M; Perez J; Smeraldi E; Zanardi R
    J Clin Psychiatry; 1997 Mar; 58(3):104-7. PubMed ID: 9108811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of fluvoxamine in body dysmorphic disorder.
    Phillips KA; Dwight MM; McElroy SL
    J Clin Psychiatry; 1998 Apr; 59(4):165-71. PubMed ID: 9590666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot study: fluvoxamine treatment for depression and anxiety disorders in children and adolescents with cancer.
    Gothelf D; Rubinstein M; Shemesh E; Miller O; Farbstein I; Klein A; Weizman A; Apter A; Yaniv I
    J Am Acad Child Adolesc Psychiatry; 2005 Dec; 44(12):1258-62. PubMed ID: 16292117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapse during a 6-month continuation treatment with fluvoxamine in an Italian population: the role of clinical, psychosocial and genetic variables.
    Dotoli D; Spagnolo C; Bongiorno F; Zanardi R; Serretti A; Smeraldi E; Franchini L
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):442-8. PubMed ID: 16431008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluvoxamine for somatoform disorders: an open trial.
    Noyes R; Happel RL; Muller BA; Holt CS; Kathol RG; Sieren LR; Amos JJ
    Gen Hosp Psychiatry; 1998 Nov; 20(6):339-44. PubMed ID: 9854645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients.
    Fabre L; Birkhimer LJ; Zaborny BA; Wong LF; Kapik BM
    Int Clin Psychopharmacol; 1996 Jun; 11(2):119-27. PubMed ID: 8803649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minor depressive disorder and subsyndromal depressive symptoms: functional impairment and response to treatment.
    Rapaport MH; Judd LL
    J Affect Disord; 1998 Mar; 48(2-3):227-32. PubMed ID: 9543213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition.
    Ushiroyama T; Ikeda A; Ueki M
    J Med; 2004; 35(1-6):151-62. PubMed ID: 18084873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of fluvoxamine in the treatment of recurrent depression in France.
    Nuijten M; Hadjadjeba L; Evans C; van den Berg J
    Pharmacoeconomics; 1998 Oct; 14(4):433-45. PubMed ID: 10344910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine.
    Smeraldi E; Zanardi R; Benedetti F; Di Bella D; Perez J; Catalano M
    Mol Psychiatry; 1998 Nov; 3(6):508-11. PubMed ID: 9857976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluvoxamine in civilians with posttraumatic stress disorder.
    Davidson JR; Weisler RH; Malik M; Tupler LA
    J Clin Psychopharmacol; 1998 Feb; 18(1):93-5. PubMed ID: 9472854
    [No Abstract]   [Full Text] [Related]  

  • 14. Possible predictors of response to fluvoxamine for depression.
    Morishita S; Arita S
    Hum Psychopharmacol; 2003 Apr; 18(3):197-200. PubMed ID: 12672171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Olanzapine in the treatment of depressive disorders with psychotic symptoms].
    Adli M; Rossius W; Bauer M
    Nervenarzt; 1999 Jan; 70(1):68-71. PubMed ID: 10087520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of fluvoxamine and fluoxetine in the treatment of major depression.
    Rapaport M; Coccaro E; Sheline Y; Perse T; Holland P; Fabre L; Bradford D
    J Clin Psychopharmacol; 1996 Oct; 16(5):373-8. PubMed ID: 8889909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four-year follow-up study of sertraline and fluvoxamine in long-term treatment of unipolar subjects with high recurrence rate.
    Franchini L; Gasperini M; Zanardi R; Smeraldi E
    J Affect Disord; 2000 Jun; 58(3):233-6. PubMed ID: 10802132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study.
    Terra JL; Montgomery SA
    Int Clin Psychopharmacol; 1998 Mar; 13(2):55-62. PubMed ID: 9669185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study.
    Zanardi R; Franchini L; Gasperini M; Lucca A; Smeraldi E; Perez J
    J Clin Psychopharmacol; 1998 Dec; 18(6):441-6. PubMed ID: 9864075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
    Morishita S; Arita S
    Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.